Eris Lifesciences cash flow

Latest FY26

Cash from operations: ₹538cr−49.5% on FY25
Capital spending: ₹297cr+91.5% on FY25
Free cash flow: ₹241cr−73.5% on FY25
Cash from financing: −₹314cr−₹881 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	280	315	183	117
	—	193	231	84.8	26.2
	—	3.5	−5.1	−7.0	−2.3
	—	0.0	0.0	−3.9	−0.0
	—	0.0	0.0	0.8	3.1
	—	13.3	0.0	−3.0	−4.2
	—	0.0	−3.0	0.0	0.0
	—	−6.9	9.4	0.0	0.0
	—	−101	−94.4	−16.9	4.7
	—	−210	−9.1	−57.1	−117
	—	−3.7	0.0	0.0	0.0
	—	−99.5	119	−16.2	−76.5
	—	−3.2	67.9	91.0	−10.5
	—	−3.2	0.0	0.0	0.0
	—	0.0	1.0	−73.4	3.6
	—	2.4	16.8	−22.4	−1.5
	—	−40.0	24.3	−3.6	21.7
Cash from operating activities
	643	638	489	431	405
	—	23.9	674	156	−35.7
	—	662	1,163	587	369
	—	124	97.9	101	77.2
	—	538	1,065	486	292
Cash from investing activities
	—	297	155	129	841
	—	0.1	0.0	0.0	0.1
	—	0.0	0.4	0.0	0.0
	—	0.0	51.4	0.0	0.0
	—	10.0	1,169	0.0	0.0
	—	0.0	0.0	1.7	0.9
	—	0.0	0.0	0.0	21.6
	—	0.0	3.9	0.0	0.0
	—	2.2	4.4	7.0	4.1
	—	−64.9	1,287	−1,704	−158
	—	−369	−80.0	−1,828	−975
Cash from financing activities
	—	0.0	0.0	4.5	2.3
	—	0.0	238	0.0	0.0
	—	0.0	0.0	10.3	0.0
	—	0.0	0.0	0.0	32.8
	—	170	1,436	1,623	1,135
	—	282	1,834	159	350
	—	0.0	8.7	0.9	8.7
	—	193	145	77.3	23.4
	—	0.0	100	0.0	99.9
	—	−8.3	7.2	0.0	0.0
	—	−314	−881	1,380	688
	—	−145	104	38.2	5.2
	—	−145	104	38.2	5.2
	—	—	—	94.2	56.0
Reference items
	1,161	1,120	1,017	675	537
	34.9%	35.8%	35.2%	33.6%	31.9%
	241	241	910	357	−550
	—	−120	508	2,185	—
	₹17.41	₹17.41	₹65.70	₹25.76	−₹39.69
	62.58×	—	—	—	—
	—	0.83×	2.84×	1.22×	0.78×
	—	124	97.9	101	77.2
	—	193	145	77.3	23.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ERIS₹1,089.60

Eris Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersMANKIND AJANTPHARM TORNTPHARM EMCURE GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹15,091 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	117.1	182.6	315.5	279.5	—
+ Finance Costs	26.2	84.8	231.3	192.7	—
+ Interest Income	-2.3	-7.0	-5.1	3.5	—
+ Fair Value (Gains) / Losses	-0.0	-3.9	0.0	0.0	—
+ Share-based Payments	3.1	0.8	0.0	0.0	—
+ Other Non-cash Items	-4.2	-3.0	0.0	13.3	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-3.0	0.0	—
+ Other Reconciling Items	0.0	0.0	9.4	-6.9	—
Changes in Working Capital
+ Inventories	4.7	-16.9	-94.4	-100.7	—
+ Trade Receivables — Current	-117.1	-57.1	-9.1	-210.3	—
+ Other Financial Assets — Current	0.0	0.0	0.0	-3.7	—
+ Other Current Assets	-76.5	-16.2	119.5	-99.5	—
+ Trade Payables — Current	-10.5	91.0	67.9	-3.2	—
+ Trade Payables — Non-current	0.0	0.0	0.0	-3.2	—
+ Other Financial Liabilities — Current	3.6	-73.4	1.0	0.0	—
+ Other Current Liabilities	-1.5	-22.4	16.8	2.4	—
+ Provisions — Current	21.7	-3.6	24.3	-40.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	404.6	431.2	488.8	638.5	642.5
+ Total Adjustments (incl. Working Capital)	-35.7	155.5	674.1	23.9	—
Cash from Operations (pre-tax)	368.9	586.8	1,162.9	662.4	—
+ Income Taxes Paid	77.2	100.8	97.9	124.4	—
Cash from Operating Activities	291.7	486.0	1,065.0	538.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	841.4	129.2	155.0	296.9	—
+ Disp of Fixed Assets	0.1	0.0	0.0	0.1	—
+ Disp of Investment Property	0.0	0.0	0.4	0.0	—
+ Acq of Interests in Joint Ventures	0.0	0.0	51.4	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	1,169.0	10.0	—
+ Loans & Advances Made	0.9	1.7	0.0	0.0	—
+ Loans & Advances Repaid	21.6	0.0	0.0	0.0	—
+ Government Grants Received	0.0	0.0	3.9	0.0	—
+ Interest Received — Investing	4.1	7.0	4.4	2.2	—
+ Other Inflows / (Outflows) — Investing	-158.1	-1,703.7	1,286.8	-64.9	—
Cash from Investing Activities	-974.6	-1,827.6	-80.0	-369.5	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	2.3	4.5	0.0	0.0	—
+ Payments for Other Equity Instruments	0.0	0.0	237.5	0.0	—
+ Payments — Change in Ownership of Subsidiaries	0.0	10.3	0.0	0.0	—
+ Proceeds from Debentures / Notes / Bonds	32.8	0.0	0.0	0.0	—
+ Proceeds from Borrowings	1,135.0	1,623.1	1,436.4	170.3	—
+ Repayment of Borrowings	350.0	159.4	1,833.7	282.3	—
+ Payment of Lease Liabilities	8.7	0.9	8.7	0.0	—
+ Interest Paid	23.4	77.3	145.1	193.3	—
+ Dividends Paid	99.9	0.0	100.1	0.0	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	7.2	-8.3	—
Cash from Financing Activities	688.0	1,379.8	-881.3	-313.5	—
Net Changes in Cash (pre-FX)	5.2	38.2	103.7	-145.0	—
Net Changes in Cash	5.2	38.2	103.7	-145.0	—
Closing Cash	56.0	94.2	—	—	—
Reference Items
EBITDA	536.7	674.8	1,017.2	1,120.1	1,160.8
EBITDA Margin %	31.85	33.59	35.15	35.79	34.86
Free Cash Flow (CFO − Capex)	-549.7	356.8	910.0	241.1	241.1
Free Cash Flow to Equity	—	2,184.8	507.6	-120.4	—
Free Cash Flow per Basic Share	-39.69	25.76	65.70	17.41	17.41
Price to Free Cash Flow	—	—	—	—	62.58
Cash Flow to Net Income	0.78	1.22	2.84	0.83	—
Cash Paid for Taxes	77.2	100.8	97.9	124.4	—
Cash Paid for Interest	23.4	77.3	145.1	193.3	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.